公开(公告)号：US20250019463A1

公开(公告)日：2025-01-16

申请号：US18711286

申请日：2022-11-17

Applicant: UCB Biopharma SRL

Inventor： Timothy Scott JOHNSON ,  Ian Trollope JAMES ,  Patricia J. SIME ,  Thomas Henry THATCHER

IPC: C07K16/40 ,  A61K39/00 ,  A61P11/00

Abstract: The present invention relates to an anti-transglutaminase type 2 antibody that blocks transamidase activity of the enzyme for use in the treatment of progressive chronic interstitial lung disease, such as Idiopathic pulmonary fibrosis (IPF).

公开(公告)号：US20250012807A1

公开(公告)日：2025-01-09

申请号：US18818247

申请日：2024-08-28

Applicant: UCB BIOPHARMA SRL

Inventor： James Philip O'CONNELL ,  John Robert PORTER ,  Alastair LAWSON ,  Boris KROEPLIEN ,  Stephen Edward RAPECKI ,  Timothy John NORMAN ,  David James MCMILLAN ,  Graham John WARRELLOW ,  Daniel Christopher BROOKINGS ,  Rikki Peter ALEXANDER

IPC: G01N33/68 ,  A61K47/64 ,  A61P35/00 ,  A61P37/00 ,  C07D213/72 ,  C07D235/04 ,  C07D239/26 ,  C07D401/14 ,  C07D471/00 ,  C07D471/04 ,  C07K14/525 ,  C07K14/705 ,  C07K16/24

Abstract: The invention is in the field of TNF signalling. Compounds have been identified which are capable of modulating signalling of TNF trimers through receptors. Methods of identifying such compounds are therefore provided. The compounds themselves have utility in therapy.

公开(公告)号：US12179128B2

公开(公告)日：2024-12-31

申请号：US17620137

申请日：2020-06-18

Applicant: UCB BIOPHARMA SRL

Inventor： Annick Gervais ,  Joel Dubisy

IPC: B01D15/32 ,  B01D15/16 ,  G01N30/34 ,  G01N30/88

Abstract: The current application provides a rapid and simple method for measuring residual pDADMAC in a sample containing a recombinant protein of interest based on the combination of use of reversed-phase hydrophobic interaction HPLC and charged aerosol detection.

公开(公告)号：US20240417434A1

公开(公告)日：2024-12-19

申请号：US18704867

申请日：2022-10-26

Applicant: UCB BIOPHARMA SRL

Inventor： Natalia RODRIGUEZ ALVAREZ ,  Csilla SIPEKY ,  Brittany Nicole VALLETTE ,  Christian Gilbert Joseph WOLFF ,  Meiyu XU

IPC: C07K14/47 ,  A61K48/00 ,  A61P25/08 ,  C12N15/86

Abstract: The present invention relates to a nucleic acid construct comprising a transgene encoding syntaxin binding protein 1 (STXBP1, Munc-18), a viral vector for packaging said nucleic acid in a viral particle; and use of such viral particle for treating disease associated with a loss of STXBP1 functional activity.

公开(公告)号：US20240415769A1

公开(公告)日：2024-12-19

申请号：US18703661

申请日：2022-10-20

Applicant: UCB Biopharma SRL

Inventor： Claude PEERBOOM ,  Michaël Joseph Edouard BOONEN

IPC: A61K9/08 ,  A61K47/02 ,  A61K47/12 ,  A61K47/18 ,  C07K16/40

Abstract: The invention relates to the field of pharmaceutical formulations. More particularly it is directed to liquid formulations comprising anti-TG2 antibodies and to methods of producing such formulations. The liquid formulations according to the invention are stable upon storage at a temperature from about 2 to 25° C. for an appropriate period of time.

公开(公告)号：US20240376191A1

公开(公告)日：2024-11-14

申请号：US18422323

申请日：2024-01-25

Applicant: UCB BIOPHARMA SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Alastair David Griffiths Lawson

IPC: C07K16/24

Abstract: The invention relates to antibody molecules having specificity for antigenic determinants of both IL-17A and IL-17F, therapeutic uses of the antibody molecules and methods for producing said antibody molecules.

公开(公告)号：US20240352083A1

公开(公告)日：2024-10-24

申请号：US18647911

申请日：2024-04-26

Applicant: UCB Biopharma SRL

Inventor： Ralph Adams ,  Terence Seward Baker ,  Xiaofeng Liu

IPC: C07K14/54 ,  C07K14/505 ,  C07K14/535 ,  C07K14/55 ,  C07K16/18 ,  C07K16/24 ,  C07K16/28

CPC classification number: C07K14/5443 ,  C07K14/505 ,  C07K14/535 ,  C07K14/5428 ,  C07K14/55 ,  C07K16/18 ,  C07K16/244 ,  C07K16/248 ,  C07K16/2809 ,  C07K16/2818 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/567 ,  C07K2317/569 ,  C07K2317/622 ,  C07K2317/76

Abstract: The present invention provides antibodies comprising a variable (V) domain and an insert polypeptide, wherein the insert polypeptide is within the framework 3 region of the V domain.

公开(公告)号：US11975046B2

公开(公告)日：2024-05-07

申请号：US18343944

申请日：2023-06-29

Applicant: UCB BIOPHARMA SRL ,  FIVE PRIME THERAPEUTICS, INC.

Inventor： Timothy Scott Johnson ,  Breda Twomey ,  Janine Powers ,  Danielle E. Kellar

IPC: A61K38/21 ,  A61K45/06 ,  A61K47/60 ,  A61P1/00 ,  A61P1/16 ,  A61P13/12 ,  A61P17/00

CPC classification number: A61K38/21 ,  A61K45/06 ,  A61K47/60 ,  A61P1/00 ,  A61P1/16 ,  A61P13/12 ,  A61P17/00

Abstract: The present invention relates to methods for the treatment of fibrosis. The invention discloses new research which demonstrates that interferon-lambda has directly acting anti-fibrotic effects both in vitro and in vivo and may be used to provide effective new therapies for the treatment of multiple types of fibrosis.

公开(公告)号：US20240076365A1

公开(公告)日：2024-03-07

申请号：US18502188

申请日：2023-11-06

Applicant: UCB BIOPHARMA SRL

Inventor： NEESHA DEDI ,  BREDA TWOMEY ,  MICHAEL JOHN WRIGHT ,  GARETH CHARLES GLYNDWR DAVIES ,  DAVID JAMES MCMILLAN

IPC: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/68

CPC classification number: C07K16/22 ,  A61P9/12 ,  C07K14/51 ,  G01N33/6854 ,  A61K2039/505

Abstract: This invention relates to crystals of the human Gremlin-1 protein, and the human Gremlin-1 protein in complex with an inhibitory antibody. The invention also relates to the structure of human Gremlin-1 (on its own, or in complex with the antibody) and uses of these structures in screening for agents which modulate Gremlin-1 activity. The invention further provides antibodies which bind an allosteric inhibitory site on Gremlin-1, together with pharmaceutical compositions and medical uses of such antibodies and agents identified by the screening methods.

公开(公告)号：US11912721B2

公开(公告)日：2024-02-27

申请号：US17102790

申请日：2020-11-24

Applicant: UCB Biopharma SRL ,  Sanofi

Inventor： Teresa De Haro Garcia ,  Michael Deligny ,  Jag Paul Heer ,  Joanna Rachel Quincey ,  Mengyang Xuan ,  Zhaoning Zhu ,  Daniel Christopher Brookings ,  Mark Daniel Calmiano ,  Yves Evrard ,  Martin Clive Hutchings ,  James Andrew Johnson ,  Sophie Jadot ,  Jean Keyaerts ,  Malcolm MacCoss ,  Matthew Duncan Selby ,  Michael Alan Shaw ,  Dominique Louis Leon Swinnen ,  Laurent Schio ,  Yann Foricher ,  Bruno Filoche-Romme

IPC: C07D519/00 ,  C07D491/08 ,  C07D487/08 ,  C07D491/18 ,  C07D495/08 ,  C07D471/18 ,  C07D487/18 ,  C07D493/18 ,  C07D495/18 ,  C07D513/18 ,  C07F7/18 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55

CPC classification number: C07D519/00 ,  A61K31/4184 ,  A61K31/506 ,  A61K31/55 ,  C07D471/18 ,  C07D487/08 ,  C07D487/18 ,  C07D491/08 ,  C07D491/18 ,  C07D493/18 ,  C07D495/08 ,  C07D495/18 ,  C07D513/18 ,  C07F7/1804

Abstract: A series of fused pentacyclic imidazole derivatives, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders. In particular, the present invention is concerned with 6, 7-dihydro-7, 14-methanobenzimidazo[1, 2-b][2,5]benzodiazocin-5(14H)-one derivatives and analogs thereof.